ETFs with SNTS as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|3.84%||SPDR S&P Pharmaceuticals ETF (XPH)||+10.25 (13.58%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The following table provides an overview of our product portfolio: Santarus Product Portfolio Marketed and Approved Products Uceris™ (budesonide) extended release tablets Marketed for the induction of remission of active, (Rx – U.S. ... More ...